How is Haleon - the spin-off from GSK plc - doing, punk?
By Chris Bailey of Financial Orbit | Saturday 12 November 2022
Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
As per analytical data from my personal pension fund account, I have made money from my choice to retain a holding in Haleon (HLN) - “a global leader 100% focused on consumer healthcare with a competitive advantage to combine deep human understanding with trusted science” - after its spin-off from GSK plc (GSK) in July. I am not sure that is technically correct given the company’s c. 276.53p share price at the close of business on Friday. Anyhow, the bigger question is what should I do now? After all, other GSK shareholders - including Tom - decided to exit stage left kicking around a 300 pence share price immediately after the spin-off and invest elsewhere.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.